0001209191-20-065499.txt : 20201230 0001209191-20-065499.hdr.sgml : 20201230 20201230160027 ACCESSION NUMBER: 0001209191-20-065499 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201228 FILED AS OF DATE: 20201230 DATE AS OF CHANGE: 20201230 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: King Rachel K. CENTRAL INDEX KEY: 0001589712 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36177 FILM NUMBER: 201425867 MAIL ADDRESS: STREET 1: C/O GLYCOMIMETICS, INC. STREET 2: 401 PROFESSIONAL DRIVE, SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20879 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GLYCOMIMETICS INC CENTRAL INDEX KEY: 0001253689 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9708 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-243-1201 MAIL ADDRESS: STREET 1: 9708 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-28 0 0001253689 GLYCOMIMETICS INC GLYC 0001589712 King Rachel K. C/O GLYCOMIMETICS, INC. 9708 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 1 1 0 0 President, CEO Common Stock 2020-12-28 4 M 0 130821 1.12 A 440240 D Common Stock 2020-12-28 4 S 0 84176 3.91 D 356064 D Common Stock 129401 I By trusts Common Stock 45741 I By spouse Employee Stock Option (right to buy) 1.12 2020-12-28 4 M 0 130821 0.00 D 2021-01-04 Common Stock 130821 0 D This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020. This total includes 2,275 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the Reporting Person on January 10, 2020 and are now owned directly by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This total excludes the 2,275 shares transferred to the Reporting Person as described in footnote (2) above. These shares are held by family trusts, for which Ms. King serves as trustee, as follows: 1,741 shares are held by The Connor A. King 1988 Trust, 1,741 shares are held by The Langley C. King 1990 Trust, 8,796 shares are held by the 1995 Connor A. King Trust, 8,796 shares are held by the 1995 Langley C. King Trust, 23,301 shares are held by The Connor King 2013 GRAT, 23,301 shares are held by The Langley C. King 2013 GRAT and 61,725 shares are held by The Rachel K. King 2016 GRAT. The shares underlying this option are fully vested and exercisable. /s/ Brian F. Leaf, attorney-in-fact 2020-12-30